PORTAGE, Mich. / Jan 31, 2024 / Business Wire / Stryker (NYSE: SYK), a global leader in medical technologies, today announced the launch of Prophecy Footprint, an expansion of the Prophecy Surgical Planning system, offering comprehensive surgical planning across the entire foot. The system will be demonstrated at the American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting, Tampa Bay, Fla., Feb. 1-4 (booth #919).
The launch of Prophecy Footprint also coincides with the tenth anniversary of Stryker’s Infinity Total Ankle System, a low-profile implant indicated for total ankle replacement in patients with end-stage ankle arthritis. Since its launch in 2014, the Infinity Total Ankle System has been featured in multiple studies, with the largest series demonstrating 98.8% survivorship at the two-year mark.1
"Our total ankle and enabling technology portfolios are an incredible example of Stryker's legacy and its commitment to surgeon-driven innovation and enhanced patient care," said Patrick Fisher, vice president and general manager of Stryker’s Foot & Ankle business. “Celebrating a decade of remarkable success, Infinity continues to reflect our commitment to the highest levels of performance. The latest addition to our enabling technology portfolio, Prophecy Footprint, marks a significant milestone as one of the first surgical planning systems that addresses the complexities of the entire foot.” *
With 70% of patients receiving additional procedures at the time of total ankle arthroplasty2, assessing the entire foot is essential for understanding a patient-specific procedural approach. Prophecy Footprint elevates surgical planning by providing comprehensive procedural considerations that address concomitant pathology at the time of total ankle arthroplasty.
“Prophecy Footprint offers surgeons more detailed and comprehensive planning capabilities, especially crucial in complex ankle arthroplasty cases," said Dr. Hodges Davis, medical director for Stryker’s Foot and Ankle business. “It enables a more integrated approach and facilitates a more complete view of the foot around the ankle, enhancing the surgical planning experience for surgeons and, as always, the ultimate goal is better clinical outcomes for our patients.”
Prophecy Surgical Planning system’s history of innovation and success includes:
Stryker’s Foot & Ankle business will be showcasing Prophecy Footprint at the ACFAS meeting. The event will feature an engaging didactic session titled “Advancements in Surgical Planning for Total Ankle Replacement,” led by Dr. Davis and Randy Clements, DPM, that will explore how Prophecy Footprint provides insights into potential ancillary procedures, contributing to the success of total ankle replacements.7
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area.
Content ID: AP-017191
References
* As of January, 2024
Last Trade: | US$364.60 |
Daily Change: | 7.46 2.09 |
Daily Volume: | 2,828,489 |
Market Cap: | US$138.990B |
November 19, 2024 November 14, 2024 October 29, 2024 September 20, 2024 September 17, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB